YOLFTbeta
Pharvaris BV

Pharvaris BV

PHVS · NASDAQ · Healthcare / Biotechnology

33.36USD-0.47 (-1.39%)

Price History

Full chart

Market Stats

Previous Close33.83
Open33.79
Day Range32.85 – 34.28
52-Week Range20.65 – 43.25
Volume182.64K
Market Cap2.25B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.98
Dividend Yield0.00%
Beta-2.32
50-Day Avg35.32
200-Day Avg30.23

About

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Berndt Axel Edvard Modig CPA, M.B.A.
  • Employees148
  • HeadquartersGrafenauweg 8, Zug, Switzerland, 6300, USA
  • Websitehttps://pharvaris.com

Leadership

  • Mr. Berndt Axel Edvard Modig CPA, M.B.A.Co-Founder, CEO & Executive Director · b. 1959
  • Dr. Peng Lu M.D., Ph.D.President · b. 1978
  • Mr. David W. Nassif J.D.CFO, Chief Legal Officer & Corporate Secretary · b. 1954
  • Ms. Anna Nijdam M.Sc., R.A.Head of Strategic Finance & Principal Accounting Officer · b. 1981
  • Dr. Stefan Abele Ph.D.Chief Technology Operations Officer · b. 1970
  • Ms. Annick DeschoolmeesterChief Human Resources Officer · b. 1973
  • Dr. Anne A. Lesage Ph.D.Chief Early Development Officer · b. 1961
  • Mr. Wim Souverijns Ph.D.Chief Commercial Officer · b. 1971

Financials

Income Statement

Currency: EUR2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00000000
Cost of Revenue-614.478.44K80.46K150.19K252.27K--
Gross Profit--614.47-8.44K-80.46K-150.19K-252.27K--
Operating Expense-8.96M28.50M54.06M86.56M96.66M--
Operating Income-4.31M-8.97M-28.51M-54.14M-86.71M-96.91M-145.69M-169.82M
EBITDA-4.31M-8.98M-29.71M-42.31M-86.56M-99.57M-145.59M-173.29M
Net Income-4.31M-8.98M-29.62M-42.73M-76.33M-100.88M-134.22M-175.70M
R&D3.65M6.36M22.24M35.79M57.38M65.58M98.56M124.48M
Interest Expense04.38K92.47K278.18K16.11K20.05K--

Balance Sheet

Currency: EUR2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets4.80M5.43M20.60M101.10M212.09M167.73M398.69M291.37M301.45M
Total Liabilities138.84K481.34K1.92M5.31M7.14M18.47M14.65M23.61M30.18M
Total Equity4.66M4.95M18.67M95.79M204.95M149.26M384.05M267.76M271.27M
Cash4.80M5.39M20.33M98.63M209.35M161.84M391.23M280.73M291.68M
Total Debt----250.18K436.82K238.91K861.47K776.80K
Net Debt-4.80M-5.39M-20.33M-98.63M-209.10M-161.40M-390.99M-279.87M-290.90M

Cash Flow

Currency: EUR2018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.92M-6.68M-21.50M-44.60M-67.16M-93.05M-120.13M-137.07M
Investing Cash Flow-13.48K-13.48K-42.98K-130.03K-124.30K-89.98K-538.09K-164.62K
Financing Cash Flow4.51M21.63M101.20M143.67M8.65M325.39M2.68M160.61M
Capital Expenditure13.48K13.48K42.98K130.03K124.30K89.98K538.09K164.62K
Free Cash Flow-3.92M-6.69M-21.54M-44.73M-67.29M-93.14M-120.67M-137.24M
FCF to OCF100.00%100.20%100.20%100.29%100.19%100.10%100.45%100.12%

Earnings

Report DateDec 31, 2019Feb 9, 2021May 26, 2021Jul 30, 2021Nov 10, 2021Mar 29, 2022May 11, 2022Sep 12, 2022Dec 8, 2022Dec 31, 2022May 8, 2023Aug 7, 2023Nov 2, 2023Mar 6, 2024May 8, 2024Aug 14, 2024Nov 13, 2024Dec 31, 2024May 13, 2025Aug 12, 2025Nov 12, 2025Dec 31, 2025Apr 2, 2026Aug 12, 2026Nov 11, 2026
EPS Estimate0.00-1.39-0.35-0.46-0.47-0.71-0.46-0.56-0.63-0.70-0.76-0.58-0.59-0.58-0.57-0.58-0.60-0.73-0.83-0.77-0.67-0.62-0.62-0.74-0.82
EPS Actual-0.80-2.65-0.66-0.94-0.39-0.09-0.48-0.38-0.25-1.25-0.67-0.63-0.58-0.82-0.52-0.55-0.77-0.64-0.85-0.83-0.60-0.71-0.71-0.81-
Surprise--90.65%-88.57%-104.35%17.02%87.32%-4.35%32.14%60.32%-78.57%11.84%-8.62%1.69%-41.38%8.77%5.17%-28.33%11.91%-2.41%-7.79%10.45%-15.41%-14.52%-9.46%-
Timing-After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketAfter-hours-After-hoursAfter-hoursPre-market-Pre-marketPre-market-

Key Statistics & Ratios

Market Cap2.25B
Enterprise Value1.96B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.00
Price / Book6.74
EPS-2.98
Book Value4.98
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-182.17M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-70.46%
Return on Assets-42.32%
Shares Outstanding70.20M
Shares Float44.18M
Beta-2.32
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 9 analystsTarget 57.96
  • Strong Buy
    6
  • Buy
    2
  • Sell
    1

Ownership Breakdown

Institutions
93.22%
Insiders
6.08%
Retail / Other
0.70%

Top Institutional Holders

  • General Atlantic Llc
    6.55M9.33%
  • FMR Inc
    6.28M8.95%
  • Foresite Capital Management IV, LLC
    4.78M6.81%
  • venBio Partners LLC
    4.64M6.61%
  • Viking Global Investors LP
    3.65M5.20%
  • EQT Fund Management S.à r.l.
    3.42M4.88%
  • Deerfield Management Co
    3.13M4.45%
  • Bain Capital Life Sciences Investors, LLC
    2.68M3.81%
  • Wellington Management Company LLP
    2.39M3.41%
  • COMMODORE CAPITAL LP
    1.92M2.73%
  • Novo A/S
    1.75M2.49%
  • Saturn V Capital Management LLC
    1.31M1.87%
  • TCG Crossover Management, LLC
    1.01M1.44%
  • Point72 Asset Management, L.P.
    1.01M1.43%
  • Cormorant Asset Management, LLC
    1.00M1.42%
  • Sofinnova Ventures
    818.33K1.17%
  • 5AM Venture Management, LLC
    797.60K1.14%

Top Fund Holders

  • Polar Capital Healthcare Opports Inc
    1.46M2.08%
  • Fidelity Growth Company Fund
    1.37M1.96%
  • Fidelity Select Health Care
    800.00K1.14%